Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: Evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer

Journal of Controlled Release

Volumn 166, Issue 1, 2013, Pages 1-9

  Cho, Hyunah ^a   Lai, Tsz Chung ^b   Kwon, Glen S ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Bioluminescence imaging; Combination drug delivery; Ovarian cancer; Paclitaxel; PET imaging; Polymeric micelles

Indexed keywords

BIOLUMINESCENCE IMAGING; OVARIAN CANCERS; PACLITAXEL; PET IMAGING; POLYMERIC MICELLE;

BIOLOGICAL MATERIALS; BIOLUMINESCENCE; CELL CULTURE; CONTROL SYSTEM SYNTHESIS; DISEASES; DRUG DELIVERY; PHOSPHORESCENCE; POLYETHYLENE GLYCOLS; POLYETHYLENE TEREPHTHALATES; TUMORS;

MICELLES;

3' FLUOROTHYMIDINE F 18; CYCLOPAMINE; GOSSYPOL; MACROGOL; PACLITAXEL; POLYCAPROLACTONE; POLYETHYLENEGLYCOL BLOCK POLYCAPROLACTONE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MICELLE; MOUSE; NONHUMAN; OVARY CANCER; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; FEMALE; GOSSYPOL; HUMANS; INJECTIONS, INTRAPERITONEAL; KAPLAN-MEIER ESTIMATE; LACTONES; MICE; MICE, NUDE; MICELLES; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; SOLUBILITY; SURFACE PROPERTIES; TREATMENT OUTCOME; VERATRUM ALKALOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871748278     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.12.005     Document Type: Article

References (33)

1. R. Siegel, E. Ward, O. Brawley, and A. Jemal Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J. Clin. 61 2011 212 236
2. M. Harries, and M. Gore Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease Lancet Oncol. 3 2002 537 545
3. A. Ray, E. Meng, E. Reed, L.A. Shevde, and R.P. Rocconi Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells Int. J. Oncol. 39 2011 797 804
4. A.D. Steg, A.A. Katre, K.S. Bevis, A. Ziebarth, Z.C. Dobbin, M.M. Shah, R.D. Alvarez, and C.N. Landen Smoothened antagonists reverse taxane resistance in ovarian cancer Mol. Cancer Ther. 11 2012 1587 1597
5. J. Wang, J.Y. Zhou, L. Zhang, and G.S. Wu Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells Cell Cycle 8 2009 3191 3198
6. G. Bajaj, and Y. Yeo Drug delivery systems for intraperitoneal therapy Pharm. Res. 27 2010 735 738
7. M.V. Barbolina, N.M. Moss, S.D. Westfall, Y. Liu, R.J. Burkhalter, F. Marga, G. Forgacs, L.G. Hudson, and M.S. Stack Microenvironmental regulation of ovarian cancer metastasis Cancer Treat. Res. 149 2009 319 334
8. R. De Souza, P. Zahedi, R.M. Badame, C. Allen, and M. Piquette-Miller Chemotherapy dosing schedule influences drug resistance development in ovarian cancer Mol. Cancer Ther. 10 2011 1289 1299
9. D. Lu, M.G. Wientjes, Z. Lu, and J.L. Au Tumor priming enhances delivery and efficacy of nanomedicines J. Pharmacol. Exp. Ther. 322 2007 80 88
10. Z. Lu, J. Wang, M.G. Wientjes, and J.L. Au Intraperitoneal therapy for peritoneal cancer Future Oncol. 6 2010 1625 1641
11. J.K. Chen, J. Taipale, M.K. Cooper, and P.A. Beachy Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened Genes Dev. 16 2002 2743 2748
12. Y.W. Huang, L.S. Wang, H.L. Chang, W. Ye, M.K. Dowd, P.J. Wan, and Y.C. Lin Molecular mechanisms of (-)-gossypol-induced apoptosis in human prostate cancer cells Anticancer. Res. 26 2006 1925 1933
13. L. Jia, L.C. Coward, C.D. Kerstner-Wood, R.L. Cork, G.S. Gorman, P.E. Noker, S. Kitada, M. Pellecchia, and J.C. Reed Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate Cancer Chemother. Pharmacol. 61 2008 63 73
14. J.R. Hasenstein, H.C. Shin, K. Kasmerchak, D. Buehler, G.S. Kwon, K.R. Kozak, Anti-tumor activity of triolimus: a novel multi-drug loaded micelle containing paclitaxel, rapamycin and 17-Aag, Mol. Cancer Ther. (in press).
15. H. Cho, and G.S. Kwon Polymeric micelles for neoadjuvant cancer therapy and tumor-primed optical imaging ACS nano 5 2011 8721 8729
16. J. Friedrich, C. Seidel, R. Ebner, and L.A. Kunz-Schughart Spheroid-based drug screen: considerations and practical approach Nat. Protoc. 4 2009 309 324
17. K.R. Zinn, T.R. Chaudhuri, A.A. Szafran, D. O'Quinn, C. Weaver, K. Dugger, D. Lamar, R.A. Kesterson, X. Wang, and S.J. Frank Noninvasive bioluminescence imaging in small animals ILAR J. 49 2008 103 115
18. S. Dufort, L. Sancey, C. Wenk, V. Josserand, and J.L. Coll Optical small animal imaging in the drug discovery process Biochim. Biophys. Acta 1798 2010 2266 2273
19. H.J. Lee, M.N. Tantawy, K.T. Nam, I. Choi, T.E. Peterson, and R.R. Price Evaluation of an intraperitoneal ovarian cancer syngeneic mouse model using 18F-FDG MicroPET imaging Int. J. Gynecol. Cancer 21 2011 22 27
20. M.M. Jensen, K.D. Erichsen, F. Bjorkling, J. Madsen, P.B. Jensen, L. Hojgaard, M. Sehested, and A. Kjaer Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice PLoS One 5 2010 e12965
21. N. Aide, K. Kinross, C. Cullinane, P. Roselt, K. Waldeck, O. Neels, D. Dorow, G. McArthur, and R.J. Hicks 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model J. Nucl. Med. 51 2010 1559 1564
22. C.L. Zavaleta, W.T. Phillips, Y.C. Bradley, L.M. McManus, P.A. Jerabek, and B.A. Goins Characterization of an intraperitoneal ovarian cancer xenograft model in nude rats using noninvasive microPET imaging Int. J. Gynecol. Cancer 17 2007 407 417
23. V. Vassileva, E.H. Moriyama, R. De Souza, J. Grant, C.J. Allen, B.C. Wilson, and M. Piquette-Miller Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging Br. J. Cancer 99 2008 2037 2043
24. H. Devalapally, Z. Duan, M.V. Seiden, and M.M. Amiji Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles Clin. Cancer Res. 14 2008 3193 3203
25. H. Devalapally, Z. Duan, M.V. Seiden, and M.M. Amiji Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer Int. J. Cancer 121 2007 1830 1838
26. V. Vassileva, J. Grant, R. De Souza, C. Allen, and M. Piquette-Miller Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model Cancer Chemother. Pharmacol. 60 2007 907 914
27. C.K. McCann, W.B. Growdon, K. Kulkarni-Datar, M.D. Curley, A.M. Friel, J.L. Proctor, H. Sheikh, I. Deyneko, J.A. Ferguson, V. Vathipadiekal, M.J. Birrer, D.R. Borger, G. Mohapatra, L.R. Zukerberg, R. Foster, J.R. Macdougall, and B.R. Rueda Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model PLoS One 6 2011 e28077
28. J.M. Terwogt, B. Nuijen, W.W. Huinink, and J.H. Beijnen Alternative formulations of paclitaxel Cancer Treat. Rev. 23 1997 87 95
29. H.C. Shin, A.W. Alani, H. Cho, Y. Bae, J.M. Kolesar, and G.S. Kwon A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs Mol. Pharm. 8 2011 1257 1265
30. E.M. Berns, and D.D. Bowtell The changing view of high-grade serous ovarian cancer Cancer Res. 72 2012 2701 2704
31. N. Lalwani, S.R. Prasad, R. Vikram, A.K. Shanbhogue, P.C. Huettner, and N. Fasih Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment Radiographics 31 2011 625 646
32. K.L. Sodek, M.J. Ringuette, and T.J. Brown Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype Int. J. Cancer 124 2009 2060 2070
33. T.J. Shaw, M.K. Senterman, K. Dawson, C.A. Crane, and B.C. Vanderhyden Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer Mol. Ther. 10 2004 1032 1042